Stock Analysis
Organon & Co. (OGN) Stock Analysis
Organon & Co. (OGN) stock analysis covering valuation, fundamentals, technical indicators, risk, AIQ Momentum, analyst catalysts, dividends, and the current AIQ Score.
Organon & Co. (OGN) currently has an AIQ Score of 64/100, indicating a neutral setup. Value is the strongest factor at 75/100. Quality is the weakest current factor at 47/100. Technical, fundamental, catalyst, dividend, and risk evidence should be read together at the latest market-close snapshot.
OGN at a Glance
Crawlable current metrics from the latest market-close stock snapshot.
| Metric | Current |
|---|---|
| Price | $13.75 |
| AIQ Score | 64/100 |
| Overall View | Neutral |
| Technical Analysis Consensus | Buy |
| Market Cap | $3.61B |
| P/E Ratio (TTM) | 17.42 |
| Forward P/E | — |
| EPS (quarter ended 2026-06-30) | $0.41 |
| Revenue (quarter ended 2026-06-30) | $1.56B |
| Dividend Yield (TTM) | 0.58% |
| Beta | 1.52 |
| Volume | 2.56M |
| 52-week range | $5.69-$13.83 |
| RSI 14 | 55.88 |
| 50-Day SMA | $13.73 |
| 200-Day SMA | $11.32 |
| Analyst Price Target | $14.00 |
| Next Earnings | Nov 9, 2026 |
OGNOrganon & Co.
Healthcare / Drug Manufacturers - General
Relative Leader / Watch
Strong Relative Position
Latest quote
- Momentum67
- Value75
- Quality47
- Risk resilience70
- Sentiment—
OGN Stock Analysis Summary
Organon & Co. (OGN) currently has an AIQ Score of 64/100, indicating a neutral setup. Value is the strongest factor at 75/100. Quality is the weakest current factor at 47/100. Technical, fundamental, catalyst, dividend, and risk evidence should be read together at the latest market-close snapshot.
In a neutral regime, OGN has AIQ Score of 64/100 with Value base of 75/100 and fading Quality at 47/100. Wait for component alignment before adding exposure.
Value (75/100) leads while Quality (47/100) lags. This cross-factor spread creates entry timing uncertainty.
Healthcare · -0.07% stock move · OGN classified in Drug Manufacturers - General.
Current Evidence
AlgovestIQ Evidence Summary
Current consensus, supporting evidence, recent changes, and what would strengthen or weaken the view.
Is OGN Bullish or Bearish Right Now?
OGN currently has a neutral overall setup. Value is the strongest factor at 75/100, while Quality is weakest at 47/100. The current evidence suggests a mixed rather than strongly bullish or bearish setup.
- - Momentum is constructive at 67/100.
- - Risk Resilience is supportive at 70/100.
- - Price is +0.16% above its 50-day SMA.
- - Analyst target implies +1.82% upside from the latest quote.
- - Technical consensus has more buy votes than sell votes (19 vs 5).
- - No strong bearish evidence is available in the current snapshot.
Current Consensus
OGN's Technical Analysis Consensus is currently Buy, with 19 buy, 21 neutral, and 5 sell votes. OGN's 14-day RSI is 55.88, which places the stock in a constructive momentum range. OGN's beta is 1.52, indicating greater market sensitivity than the broad market.
What Changed in OGN?
The largest recent change in OGN is Momentum moving up by 3.0 points over the available 7-day comparison window. Value remains the strongest visible factor.
What Would Change the OGN Outlook?
The current neutral outlook could improve if AIQ moves above 70, momentum recovers, earnings revisions strengthen, and price confirms a stronger trend above the 50-day and 200-day moving averages. It would weaken if AIQ falls below 40, price loses long-term moving-average support, analyst expectations deteriorate, or risk evidence worsens.
AIQ > 70, RSI above 55, price above SMA-50/SMA-200, and positive catalyst or estimate-revision evidence.
AIQ below 40, RSI below 45, loss of SMA-200, negative revisions, or rising volatility and drawdown risk.
OGN Decision Framework
Public evidence layers, setup checks, and risk context for Organon & Co..
Organon & Co. (OGN) Stock Analysis
Organon & Co. has an AIQ Score of 64/100 in a Neutral regime. Value is strongest at 75/100. Beta is 1.54, above market sensitivity. Review the supporting stock factors together before drawing a conclusion from any single score.
| Evidence Layer | Public Evidence |
|---|---|
| Regime Context | OGN is in a Neutral AIQ regime with score 64/100. |
| Signal Conflict | The primary conflict is that value leads at 75/100 while quality lags at 47/100. |
| Factor Evidence | Momentum 67/100 · Value 75/100 · Quality 47/100 · Risk 70/100 |
| Persistence | Current snapshot evidence is shown; historical persistence remains in AIQ Pro. |
Current Setup Checklist
Value is the strongest factor at 75/100.
Momentum is 67/100 and RSI (14) is 55.9.
OGN is in a Neutral regime at 64/100.
Risk factor is 70/100 with beta 1.54 and annual volatility 66.65%.
Current conflict: value leads at 75/100 while quality lags at 47/100.
OGN Research Cluster
Ticker-specific paths for valuation, technical analysis, catalysts, dividends, financials, risk, and news.
OGN Fundamentals
OGN valuation, profitability, growth, margins, balance-sheet strength, and free cash flow.
OGN Technical Analysis
OGN technical setup based on RSI, MACD, moving averages, AIQ Momentum, volume, trend, volatility, and pivots.
OGN Stock Catalysts
Track OGN earnings, analyst ratings, price targets, estimate revisions, stock news, and upcoming events.
OGN Dividend Analysis
OGN dividend yield, annual dividend, payout ratio, payment history, and income reliability context.
OGN Financial Data
OGN revenue, earnings, income statement, balance sheet, cash flow, valuation ratios, and stock metrics.
OGN Risk Analysis
OGN volatility, beta, drawdown, Sharpe ratio, VaR, and downside resilience.
OGN Stock News
OGN stock news, market tone, recent headlines, and catalyst context.
OGN vs Large Cap Pharma Peers
Current peer cohort: OGN · PFE · REGN · RPRX · TEVA. Compare AIQ, factor scores, Sharpe ratio and 1-year volatility in one indexable view.
| Peer | AIQ | Value | Momentum | Risk | Sharpe | 1Y Volatility | Compare |
|---|---|---|---|---|---|---|---|
| OGN Current stock | 64/100 | 75/100 | 67/100 | 70/100 | 0.86 | 66.65% | Current |
| PFE Pfizer | 64/100 | 67/100 | 79/100 | 54/100 | 0.81 | 21.51% | OGN vs PFE |
| REGN Regeneron Pharmaceuticals | 69/100 | 48/100 | 95/100 | 61/100 | 1.05 | 33.45% | OGN vs REGN |
| RPRX Royalty Pharma | 59/100 | 51/100 | 80/100 | 51/100 | 2.19 | 23.74% | OGN vs RPRX |
| TEVA Teva Pharmaceutical | 56/100 | 65/100 | 72/100 | 54/100 | 1.98 | 39.26% | OGN vs TEVA |
Peer cohort is resolved dynamically from the AlgovestIQ universe taxonomy and Compare relationship graph. Data as of Oct 21, 2026.
About the AIQ Score
Methodology for the current stock evidence.
The AlgovestIQ AIQ Score combines multiple dimensions of stock evidence, including momentum, valuation exposure, quality, risk resilience, sentiment context, and timing signals. It is a descriptive research score, not a guarantee of future performance or a personalized recommendation.
View AIQ methodologyFactor Diagnostics
A compact bridge from the AIQ score to the evidence tabs.
Open the return calculator with stock context while purchase price, shares, dates and fees remain user inputs.
AIQ Component Profile
Compare the five component scores on one consistent 0–100 scale.
Review earnings timing, revisions, news pressure, and prior event reactions in one place.
Open catalysts3 recent quarterly periods are available for review.
Checked Oct 21, 2026
Explore factor drivers, conflicts, persistence, and scenario sensitivity in the advanced workspace.
Fundamentals Verdict
Current snapshot fields are separate from reported-quarter statement tables.
Latest period Jun 30, 2026.
Market Confirmation
Technicals are summarized first, with the indicator library behind it.
Risk Alignment
Higher resilience is stronger; exposure metrics stay separate.
Continue Researching OGN
Open the detailed evidence pages and workflows behind the stock overview read.
Premium Feature
Full AIQ Analysis
AIQ Intelligence
AIQ Pro for OGN
Scenario Analysis
AIQ Scenario Builder
Portfolio Implication
Related Links
OGN Stock FAQ
What is OGN stock price today?
Organon & Co.'s current stock price is $13.75. Use the live quote with AIQ Score, news, and risk context rather than treating price alone as a decision signal.
Is OGN bullish or bearish right now?
OGN's bullish or bearish read depends on the current AIQ Score, factor alignment, technical analysis consensus, valuation, risk, and catalyst evidence. A mixed setup should be treated differently from a broad confirmation across those signals.
What is OGN's market cap?
OGN's market cap is $3.61B based on the latest completed market-close snapshot from Oct 21, 2026. Use it with P/E ratio, revenue, and growth metrics to frame company size, valuation, and peer comparisons.
What is OGN's current P/E ratio?
OGN's current P/E ratio is 17.42 based on the latest completed market-close snapshot from Oct 21, 2026. Read it with revenue growth, margins, EPS, cash flow, and peer valuation rather than using P/E alone.
What is OGN's RSI?
OGN's 14-day RSI is 55.88 based on the latest completed market-close snapshot from Oct 21, 2026. RSI should be interpreted with MACD, moving averages, volume, volatility, and price trend.
Is OGN above its 50-day and 200-day moving averages?
OGN is 0.16% from its 50-day SMA and 21.43% from its 200-day SMA based on the latest completed market-close snapshot from Oct 21, 2026. Moving-average position should be read with momentum and broader AIQ evidence.
When is OGN's next earnings date?
OGN's next earnings date is currently listed as Nov 9, 2026. Earnings can reset revenue, EPS, price target, analyst rating, and catalyst expectations.
Does OGN pay a dividend?
OGN's dividend yield is 0.58% based on the latest completed market-close snapshot from Oct 21, 2026. Dividend yield should be read with payout ratio, free cash flow, growth, and balance-sheet strength.